CELC · NASDAQ
Celcuity Inc.
$63.20 -0.04 (-0.06%)
Company overview
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focuses on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It has a license agreement with Pfizer, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $3.1B
- Employees
- 155
- Headquarters
- Minneapolis, MN
- Website
- celcuity.com
- CEO
- Brian F. Sullivan
- Listed
- September 19, 2017
- P/E
- -16.25
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$47,000
- Operating income
- -$187M
- EBITDA
- -$173M
- Net income
- -$193M
- EPS
- -$3.89
- Total assets
- $410M
- Total debt
- $196M
- Earnings yield
- -6.16%
CELC
1D
NASDAQ
O65.00H66.19L63.49C65.53-0.04 (-0.06%)Vol442.80K